Jacobs Levy Equity Management’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $280K | Sell |
4,466
-7,096
| -61% | -$494K | ﹤0.01% | 889 |
|
|
2025
Q4 | $767K | Sell |
11,562
-665
| -5% | -$43K | ﹤0.01% | 732 |
|
|
2025
Q3 | $823K | Sell |
12,227
-1,360,740
| -99% | -$108M | ﹤0.01% | 753 |
|
|
2025
Q2 | $120M | Buy |
1,372,967
+1,031,107
| +302% | +$80.8M | 0.47% | 51 |
|
|
2025
Q1 | $23.3M | Buy |
341,860
+264,459
| +342% | +$21.6M | 0.09% | 209 |
|
|
2024
Q4 | $6.02M | Buy |
77,401
+42,792
| +124% | +$3.17M | 0.02% | 396 |
|
|
2024
Q3 | $2.32M | Buy |
34,609
+30,058
| +660% | +$2.47M | 0.01% | 574 |
|
|
2024
Q2 | $516K | Hold |
4,551
| – | – | ﹤0.01% | 831 |
|
|
2024
Q1 | $631K | Hold |
4,551
| – | – | ﹤0.01% | 792 |
|
|
2023
Q4 | $565K | Sell |
4,551
-2,984
| -40% | -$305K | ﹤0.01% | 811 |
|
|
2023
Q3 | $703K | Sell |
7,535
-15,320
| -67% | -$1.73M | ﹤0.01% | 738 |
|
|
2023
Q2 | $2.94M | Sell |
22,855
-52,744
| -70% | -$6.38M | 0.02% | 497 |
|
|
2023
Q1 | $8.78M | Buy |
75,599
+2,001
| +3% | +$224K | 0.05% | 308 |
|
|
2022
Q4 | $8.33M | Sell |
73,598
-8,868
| -11% | -$974K | 0.06% | 307 |
|
|
2022
Q3 | $6.64M | Sell |
82,466
-58,238
| -41% | -$4.93M | 0.05% | 334 |
|
|
2022
Q2 | $10.5M | Buy |
140,704
+123,232
| +705% | +$11.2M | 0.08% | 269 |
|
|
2022
Q1 | $2.23M | Sell |
17,472
-66,148
| -79% | -$7.24M | 0.02% | 600 |
|
|
2021
Q4 | $11.2M | Buy |
+83,620
| New | +$12M | 0.08% | 279 |
|
|
2021
Q2 | – | Sell |
-253,196
| Closed | -$22.7M | – | 1050 |
|
|
2021
Q1 | $22.7M | Buy |
253,196
+23,460
| +10% | +$2.2M | 0.18% | 153 |
|
|
2020
Q4 | $21.2M | Buy |
+229,736
| New | +$20.5M | 0.19% | 134 |
|
|
2020
Q3 | – | Sell |
-47,680
| Closed | -$4.83M | – | 1045 |
|
|
2020
Q2 | $4.83M | Buy |
47,680
+4,240
| +10% | +$379K | 0.05% | 347 |
|
|
2020
Q1 | $2.92M | Buy |
+43,440
| New | +$2.7M | 0.04% | 406 |
|
|
2019
Q4 | – | Sell |
-57,352
| Closed | -$2.14M | – | 1014 |
|
|
2019
Q3 | $2.14M | Buy |
+57,352
| New | +$2.23M | 0.03% | 496 |
|
|
2018
Q4 | – | Sell |
-44,320
| Closed | -$1.58M | – | 999 |
|
|
2018
Q3 | $1.58M | Sell |
44,320
-5,760
| -12% | -$179K | 0.02% | 565 |
|
|
2018
Q2 | $1.19M | Buy |
+50,080
| New | +$1.06M | 0.02% | 622 |
|
|
2017
Q2 | – | Sell |
-372,160
| Closed | -$7.88M | – | 950 |
|
|
2017
Q1 | $7.88M | Sell |
372,160
-278,720
| -43% | -$5.44M | 0.16% | 187 |
|
|
2016
Q4 | $9.71M | Buy |
+650,880
| New | +$11.5M | 0.19% | 165 |
|
|
2016
Q2 | – | Sell |
-22,200
| Closed | -$377K | – | 1169 |
|
|
2016
Q1 | $377K | Sell |
22,200
-5,600
| -20% | -$93.5K | 0.01% | 808 |
|
|
2015
Q4 | $569K | Hold |
27,800
| – | – | 0.01% | 537 |
|
|
2015
Q3 | $597K | Sell |
27,800
-97,880
| -78% | -$2.18M | 0.01% | 555 |
|
|
2015
Q2 | $2.51M | Sell |
125,680
-178,708
| -59% | -$3.14M | 0.05% | 333 |
|
|
2015
Q1 | $4.74M | Buy |
304,388
+41,080
| +16% | +$621K | 0.08% | 234 |
|
|
2014
Q4 | $3.62M | Sell |
263,308
-34,800
| -12% | -$426K | 0.06% | 295 |
|
|
2014
Q3 | $2.98M | Sell |
298,108
-41,400
| -12% | -$423K | 0.05% | 319 |
|
|
2014
Q2 | $3.37M | Sell |
339,508
-404,592
| -54% | -$3.59M | 0.06% | 330 |
|
|
2014
Q1 | $7.69M | Buy |
744,100
+510,564
| +219% | +$5.28M | 0.13% | 211 |
|
|
2013
Q4 | $2.07M | Buy |
+233,536
| New | +$1.85M | 0.03% | 426 |
|
Other funds holding DXCM
VCM
VPM
Jacobs Levy Equity Management's DXCM Position: Q1 2026 in Review
Jacobs Levy Equity Management reduced its DexCom (DXCM) stake by 61% in Q1 2026, selling an estimated $494K and leaving 4,466 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #889.
Jacobs Levy Equity Management first reported a position in DXCM in Q4 2013 and has held it in 37 quarters since. The position peaked at $120M in Q2 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Jacobs Levy Equity Management held 4,466 shares of DexCom worth $280K as of Q1 2026.
- Jacobs Levy Equity Management sold 7,096 DexCom shares in Q1 2026, an estimated $494K.
- DexCom made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #889 holding.
- Jacobs Levy Equity Management first reported a position in DexCom in Q4 2013 and has held it in 37 quarters since.
- Jacobs Levy Equity Management's DexCom position peaked at $120M in Q2 2025.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.